Cormedix (HAM:19KA) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 04, 2026)


HAM:19KA Cormedix Inc HAM:19KA
39 GF Score
Price €7.66
GF Value €56.28
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Cormedix's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HAM:19KA vs STTK, ACHV, EIKN: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Cormedix's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cormedix Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Cormedix's Margin of Safety % (DCF Dividends Based) falls into.


HAM:19KA
39GF Score
Cormedix Inc HAM:19KA
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.66 is trading 86.4% below its estimated GF Value™ of €56.28. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €56.28 vs. price of €7.66 (86.4% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
39GF Score

Get the complete analysis for HAM:19KA

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.66
Price
€56.28
GF Value